Huansha Yu

2.3k total citations · 1 hit paper
33 papers, 1.1k citations indexed

About

Huansha Yu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Huansha Yu has authored 33 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Huansha Yu's work include Lung Cancer Diagnosis and Treatment (11 papers), interferon and immune responses (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Huansha Yu is often cited by papers focused on Lung Cancer Diagnosis and Treatment (11 papers), interferon and immune responses (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Huansha Yu collaborates with scholars based in China, United States and United Kingdom. Huansha Yu's co-authors include Chen Wang, Ye Cui, Senlin Li, Yijun Tang, Wei Chen, Qiang Wang, Xing Liu, Youdong Pan, Lele Zhang and Peng Zhang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Immunity and Advanced Functional Materials.

In The Last Decade

Huansha Yu

32 papers receiving 1.1k citations

Hit Papers

Tumor microenvironment remodeling after neoadjuvant immun... 2023 2026 2024 2025 2023 50 100 150

Peers

Huansha Yu
Ryan Duggan United States
Paula Carroll United Kingdom
Assaf Marcus United States
Kei‐ichiro Arimoto United States
Michael Y.K. Leung United States
Michelle Kinder United States
Ryan Duggan United States
Huansha Yu
Citations per year, relative to Huansha Yu Huansha Yu (= 1×) peers Ryan Duggan

Countries citing papers authored by Huansha Yu

Since Specialization
Citations

This map shows the geographic impact of Huansha Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huansha Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huansha Yu more than expected).

Fields of papers citing papers by Huansha Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huansha Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huansha Yu. The network helps show where Huansha Yu may publish in the future.

Co-authorship network of co-authors of Huansha Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Huansha Yu. A scholar is included among the top collaborators of Huansha Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huansha Yu. Huansha Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bian, Dongliang, Wentian Zhang, Fenghuan Sun, et al.. (2025). Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial. BMC Medicine. 23(1). 429–429. 1 indexed citations
2.
Sun, Liangdong, Jue Wang, Huansha Yu, et al.. (2025). Selective inhibition of TGF-β-induced epithelial-mesenchymal transition overcomes chemotherapy resistance in high-risk lung squamous cell carcinoma. Communications Biology. 8(1). 152–152. 1 indexed citations
3.
Shen, Ziyun, Lele Zhang, Huansha Yu, et al.. (2024). Spread Through Air Spaces in Stage I Pulmonary Large Cell Neuroendocrine Carcinoma. The Annals of Thoracic Surgery. 118(2). 385–393. 5 indexed citations
4.
Zhu, Tieyuan, Jing Zhang, Qing Yang, et al.. (2024). Optimal surgical timing for lung cancer following SARS-CoV-2 infection: a prospective multicenter cohort study. BMC Cancer. 24(1). 1250–1250. 2 indexed citations
5.
Chen, Yan, Jue Wang, Junjie Hu, et al.. (2024). MAZ promotes tumor proliferation and immune evasion in lung adenocarcinoma. Oncogene. 43(50). 3619–3632. 4 indexed citations
6.
Jiang, Cong, Xianglong Li, Fen Pan, et al.. (2023). Ferroptosis and Pyroptosis Co‐Activated Nanomodulator for “Cold” Tumor Immunotherapy and Lung Metastasis Inhibition. Advanced Functional Materials. 33(37). 35 indexed citations
7.
Hu, Junjie, Lele Zhang, Haoran Xia, et al.. (2023). Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Medicine. 15(1). 14–14. 152 indexed citations breakdown →
8.
Bian, Dongliang, et al.. (2023). The efficacy and safety of wedge resection for peripheral stage IA lung adenocarcinoma: a real-world study based on a single center. Journal of Thoracic Disease. 15(1). 54–64. 3 indexed citations
9.
Shen, Ziyun, Dongliang Bian, Jing Zhang, et al.. (2023). The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer. Cancer Immunology Immunotherapy. 72(12). 4235–4247. 1 indexed citations
10.
11.
Wang, Jin, Dongbo Jiang, Xiaoqi Zheng, et al.. (2022). Tertiary lymphoid structure and decreased CD8+ T cell infiltration in minimally invasive adenocarcinoma. iScience. 25(3). 103883–103883. 13 indexed citations
12.
Han, Lu, Jing Zhang, Yan Chen, et al.. (2022). Significance of spread through air spaces in small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 149(8). 5301–5308. 2 indexed citations
13.
Li, Dianke, Huansha Yu, Junjie Hu, et al.. (2022). Comparative profiling of single-cell transcriptome reveals heterogeneity of tumor microenvironment between solid and acinar lung adenocarcinoma. Journal of Translational Medicine. 20(1). 423–423. 13 indexed citations
14.
Li, Chenhui, Lele Zhang, Hai Hu, et al.. (2021). RNF111-facilitated neddylation potentiates cGAS-mediated antiviral innate immune response. PLoS Pathogens. 17(3). e1009401–e1009401. 37 indexed citations
15.
Hu, Junjie, Huansha Yu, Liangdong Sun, et al.. (2021). Identification of an Individualized Metabolism Prognostic Signature and Related Therapy Regimens in Early Stage Lung Adenocarcinoma. Frontiers in Oncology. 11. 650853–650853. 8 indexed citations
16.
Chu, Lei, Chenhui Li, Yongxing Li, et al.. (2021). Perillaldehyde Inhibition of cGAS Reduces dsDNA-Induced Interferon Response. Frontiers in Immunology. 12. 655637–655637. 31 indexed citations
17.
Zhang, Lele, Ning Wei, Ye Cui, et al.. (2018). The deubiquitinase CYLD is a specific checkpoint of the STING antiviral signaling pathway. PLoS Pathogens. 14(11). e1007435–e1007435. 63 indexed citations
18.
Liu, Heng, Lele Zhang, Jin Sun, et al.. (2017). Endoplasmic Reticulum Protein SCAP Inhibits Dengue Virus NS2B3 Protease by Suppressing Its K27-Linked Polyubiquitylation. Journal of Virology. 91(9). 29 indexed citations
19.
Chen, Wei, Senlin Li, Huansha Yu, et al.. (2016). ER Adaptor SCAP Translocates and Recruits IRF3 to Perinuclear Microsome Induced by Cytosolic Microbial DNAs. PLoS Pathogens. 12(2). e1005462–e1005462. 54 indexed citations
20.
Huang, Yuefeng, Heng Liu, Senlin Li, et al.. (2014). MAVS-MKK7-JNK2 Defines a Novel Apoptotic Signaling Pathway during Viral Infection. PLoS Pathogens. 10(3). e1004020–e1004020. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026